Materials and methods for treatment of autosomal dominant cone-rod dystrophy

Patent metadata

Field	Value
Publication number	US-10995328-B2
Application number	US-202016899717-A
Country	US
Kind code	B2
Filing date	Jun 12, 2020
Priority date	Dec 14, 2017
Publication date	May 4, 2021
Grant date	May 4, 2021

Abstract

The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.

First claim

What is claimed is:

1. A method for editing a guanylate cyclase 2D (GUCY2D) gene comprising an R838H, R838C or R838S mutation, comprising:
introducing into a human cell one or more S. pyogenes or S. aureus Cas9 endonucleases and one or more guide RNAs (gRNAs) comprising a spacer sequence selected from the group consisting of nucleic acid sequences in SEQ ID NOs: 5282-5313, 5398-5409 and 5434-5443,
thereby effecting one or more single stranded breaks (SSBs) or double stranded breaks (DSBs) within or near the R838H, R838C or R838S mutation of the GUCY2D gene that results in an edited human cell.

2. The method of claim 1 , wherein the edited human cell comprises a deletion, insertion or correction.

3. The method of claim 2 , wherein the deletion, insertion or correction restores retinal membrane guanylate cyclase-1 (RetGC1) protein activity.

4. The method of claim 1 , wherein the method comprises introducing into the human cell one or more polynucleotides encoding the one or more endonucleases.

5. The method of claim 1 , wherein the one or more gRNAs are single-molecule guide RNAs (sgRNAs).

6. The method of claim 1 , wherein the one or more endonucleases is pre-complexed with one or more gRNAs.

7. The method of claim 5 , wherein the one or more endonucleases is pre-complexed with one or more sgRNAs.

8. The method of claim 1 , further comprising introducing into the human cell a polynucleotide donor template comprising at least a portion of the wild-type GUCY2D gene, or cDNA.

9. A method for editing GUCY2D gene comprising an R838H mutation comprising:
introducing into a human cell one or more S. pyogenes or S. aureus Cas9 endonucleases and one or more RNAs comprising a spacer sequence selected from the group consisting of nucleic acid sequences in SEQ ID NOs: 5282-5293, 5398-5409 and 5434-5443,
thereby effecting one or more SSBs or double stranded breaks DSBs within or near the R838H mutation of the GUCY2D gene that results in an edited human cell.

10. The method of claim 9 , wherein the edited human cell comprises a deletion, insertion or correction.

11. The method of claim 10 , wherein the deletion, insertion or correction restores retinal membrane guanylate cyclase-1 (RetGC1) protein activity.

12. The method of claim 9 , wherein the method comprises introducing into the human cell one or more polynucleotides encoding the one or more endonucleases.

13. The method of claim 9 , wherein the one or more gRNAs are single-molecule guide RNAs (sgRNAs).

14. The method of claim 9 , wherein the one or more endonucleases is pre-complexed with one or more gRNAs.

15. The method of claim 13 , wherein the one or more endonucleases is pre-complexed with one or more sgRNAs.

16. The method of claim 9 , further comprising introducing into the human cell a polynucleotide donor template comprising at least a portion of the wild-type GUCY2D gene, or cDNA.

Assignees

• Crispr Therapeutics Ag
• Bayer Healthcare Llc

Inventors

• Takeuchi Ryo
• Noma Akiko
• He Shuying
• Scaria Abraham

Classifications

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N15/86

  Viral vectors · CPC title

• C12N2750/14143

  viral genome or elements thereof as genetic vector · CPC title

• C12N15/907 Primary

  in mammalian cells · CPC title